German economy to see nil growth in 2025, 1% growth in 2026: GCEE
The German economy, which is still in a phase of 'pronounced weakness', is expected to stagnate this year and grow by only 1 per cent in 2026, according to the German Council of Economic Experts, an independent academic body that advises on economic policy issues.
Bureaucratic requirements and long approval procedures are slowing down overall economic growth.
Germany's economy, in 'pronounced weakness', is expected to stagnate this year and grow by 1 per cent in 2026, the German Council of Economic Experts said. Bureaucratic needs and long approval procedures are slowing down growth. Average CPI inflation is likely to be 2.1 per cent in 2025 and fall to 2 per cent in 2026. US trade policy places an additional burden on the already weak German exports.
If funds from the recently-announced fiscal package are spent on additional investment, this will modernise the country's infrastructure and increase growth in the medium term, it noted.
Debt-financing public consumption should be avoided, and institutional precautions should be taken to ensure investment-orientated use of the funds, it cautioned in its Spring Report 2025.
Unnecessary bureaucracy should be reduced more consistently than in the past in order to relieve the burden on companies.
'In the near future, the German economy will be significantly influenced by two factors: US trade policy and the fiscal package,' explained GCEE chair Monika Schnitzer.
'US trade policy places an additional burden on the already weak German exports. With a sharp and unpredictable rise in tariffs, German exports are likely to decline even further,' she noted.
Consumer price inflation is expected to be 2.1 per cent on an average in 2025 and fall slightly to 2 per cent in 2026.
'Although markets anticipate interest rate cuts, the inflation outlook remains highly uncertain. For instance, it is unclear whether ongoing trade conflicts will fuel or dampen inflation. In addition, expansionary fiscal policies in Germany could raise inflation expectations, potentially prompting the ECB to favour a more restrictive monetary policy stance,' explained Veronika Grimm, council member .
Fibre2Fashion News Desk (DS)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
BioNtech to buy CureVac in $1.25 billion share deal to boost cancer focus
German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments. Under the agreed deal, which pairs two former rivals in the race to develop COVID-19 vaccines, each CureVac share will be exchanged for about $5.46 in BioNTech American depositary shares, or ADS, BioNTech said. The deal further underscores BioNTech's costly long-term ambition to focus on new cancer treatments and show that its success as Pfizer's COVID-19 vaccine partner, which left its balance sheet flush with billions of euros in cash, was not a fluke. "With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialization of investigational mRNA-based cancer immunotherapy," it said. CureVac about a year ago opted to focus on oncology when it agreed to sell its remaining influenza and COVID-19 vaccine development to its alliance partner, Britain's GSK. It had previously cut jobs as it sought to move beyond its failure to develop an mRNA-based COVID vaccine during the pandemic. BioNTech last week won a major shot in the arm for its cancer drug activities when Bristol Myers Squibb agreed to pay up to $11.1 billion to jointly develop a next-generation cancer immunotherapy that could take on rival Merck & Co's best-selling drug Keytruda. The company said payment in BioNTech shares would be subject to a collar mechanism - if the 10-day volume-weighted average price of BioNTech ADS shortly before the closing of the offer exceeds $126.55, the exchange ratio would be 0.04318, and if the price is lower than $84.37, the exchange ratio would be 0.06476. CureVac shareholders are expected to own between 4% and 6% of BioNTech after the deal closes, it added.
Time of India
3 hours ago
- Time of India
German medical tech firm Brainlab plans Frankfurt IPO in coming weeks
Berlin: German medical technology firm Brainlab is planning an initial public offering on the Frankfurt Stock Exchange in the coming weeks, the company said on Thursday. The Munich-based company said it will list on the regulated market and aims to raise up to 200 million euros ($230 million) through the issuance of new shares. The firm will use the capital increase to grow its business, with a focus on expanding into additional clinical applications, as well as strengthen its balance sheet. The current owners also plan to place additional secondary shares to ensure significant free float, said the company. Majority shareholder Stefan Vilsmeier , who founded the company 35 years ago and recently announced his retirement from the operational business, is set to continue to support the company as a long-term investor. The initial public offering is being organised by Berenberg, Deutsche Bank, Commerzbank, Jefferies, and UniCredit. Evercore is also advising the company, which has around 2,000 employees. Brainlab's main products include software systems that are used as navigational tools by surgeons, for example during brain and hip surgery, and for spinal implants and fractures.
Fibre2Fashion
4 hours ago
- Fibre2Fashion
US billionaire Peter Kern acquires Italian lingerie label La Perla
Peter Kern, former chief executive of US travel technology company Expedia will be the new owner of troubled Italian luxury lingerie label La Perla, the Italian government announced recently. Kern submitted the best offer for the firm through his luxury holding, both in economic and employment terms, Italian Minister of Enterprise and Made in Italy Adolfo Urso announced at the La Perla roundtable held at Palazzo Piacentini. Peter Kern, former CEO of US travel tech firm Expedia will be the new owner of troubled Italian luxury lingerie label La Perla. Kern submitted the best offer, both in economic and employment terms, Italian Minister of Enterprise and Made in Italy Adolfo Urso announced recently. Kern committed to investing around $34.31 million by 2027, avoiding redundancies and reviving production, he said. Kern committed to investing around €30 million (~$34.31 million) by 2027, avoiding redundancies and reviving production at the brand's factory in Bologna, the minister said. Kern already owns Brunello di Montalcino vineyards in Tuscany. La Perla began operations in 1954 as a corset company in Bologna, and later expanded into lingerie, swimwear and nightwear. It was run by the family of its founder, Ada Masotti, until 2008 when it was sold to San Francisco-based buyout firm JH Partners, which already held a controlling stake. The company continued to struggle after it was snapped up by German entrepreneur Lars Windhorst in 2018 at another judicial auction. The turnaround plan presented by Kern, to be finalised over the coming weeks after talks with unions, should increase employment levels to around 250 from the 210 now, Urso said. The Italian government will this week approve furlough schemes to offer financial cover for La Perla's idled workers until the transaction is completed, the minister added. Fibre2Fashion News Desk (DS)
